Intended for healthcare professionals only.

ZYDELIG® dosing

1 pill, twice daily

ZYDELIG offers convenient oral dosing1

150 mg PO BID

Recommended dosage

Bottle of ZYDELIG® (idelalisib) 150 mg tablets.

100 mg PO BID

Available for managing select AEs

Bottle of ZYDELIG® (idelalisib) 100 mg tablets.

Pill images and bottles are not actual size.

Taking ZYDELIG

  • Swallow tablets whole. ZYDELIG can be taken with or without food until disease progression or unacceptable toxicity1
  • If a planned dose of ZYDELIG is missed by less than 6 hours, take the missed dose as soon as possible and take the next dose as usual. If a dose of ZYDELIG is missed by more than 6 hours, skip the missed dose and take the next dose at the usual time1
  • No dosage modification is recommended for lymphocytosis, which has been observed in some patients taking ZYDELIG. This observed lymphocytosis is a pharmacodynamic effect and should not be considered progressive disease in the absence of other clinical findings1

Provide PJP prophylaxis during treatment with ZYDELIG

  • Serious or fatal PJP or CMV occurred in <1% of patients treated with ZYDELIG1

View additional details and clinical trials experience with 100 mg dose

Go to adverse event monitoring & management

Efficacy in relapsed
CLL

Learn more

Adverse event monitoring &
management

Learn more

ZYDELIG®
AccessConnect®

Call to learn more 1-844-622-2377

AE=adverse event; BID=twice daily; CMV=cytomegalovirus; CrCl=creatinine clearance; PJP=Pneumocystis jirovecii pneumonia; PO=orally.

Reference:

  1. ZYDELIG® (idelalisib) [Prescribing Information]. Foster City, CA: Gilead Sciences, Inc.; rev February 2022.